Compare PFLT & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFLT | SNN |
|---|---|---|
| Founded | 2010 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.0M | 14.0B |
| IPO Year | N/A | 1999 |
| Metric | PFLT | SNN |
|---|---|---|
| Price | $9.04 | $32.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | $10.75 | ★ $32.83 |
| AVG Volume (30 Days) | ★ 927.2K | 496.7K |
| Earning Date | 11-24-2025 | 03-02-2026 |
| Dividend Yield | ★ 13.62% | 2.23% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | ★ 0.72 | 0.56 |
| Revenue | $261,427,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $11.01 | $7.78 |
| Revenue Next Year | $0.14 | $5.13 |
| P/E Ratio | ★ $12.59 | $28.55 |
| Revenue Growth | ★ 40.28 | 5.35 |
| 52 Week Low | $8.40 | $23.69 |
| 52 Week High | $11.50 | $38.79 |
| Indicator | PFLT | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 46.72 |
| Support Level | $9.14 | $32.06 |
| Resistance Level | $9.62 | $33.60 |
| Average True Range (ATR) | 0.15 | 0.43 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 1.65 | 44.86 |
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.